Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659204 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel
A Phase 3 study, sponsored by Madigan Army Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT00659204 is a Phase 3 study that was terminated before completion, run by Madigan Army Medical Center. The registered enrollment target is 22 participants.
The verdict
NCT00659204, a Phase 3 study, was terminated before completion, sponsored by Madigan Army Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to compare the antimicrobial efficacy of silver nanoparticle gel to a commercialized alcohol-based hand gel on bacterial counts isolated from the hands of 40 volunteers seeded with Serratia marcescens, a surrogate microbial marker. Specific aims of this study are: Aim #1: Compare the immediate antimicrobial efficacy of a one-time application of silver nanoparticle gel (SilvaSorb , AcryMed, Inc., Portland, OR) versus an alcohol-based hand gel (Purell, GoJo Industries, Akron, OH) in reducing transient bacterial counts isolated from hands seeded with S. marcescens. Aim # 2: Compare the persistent antimicrobial efficacy of a one-time application of silver nanoparticle gel (SilvaSorb) versus an alcohol-based hand gel (Purell) over a 10 minute time frame in producing a persistent reduction on transient bacterial counts isolated from hands seeded with S. marcescens. Aim # 3: Compare user acceptability of silver nanoparticle gel (SilvaSorb) versus an alcohol-based hand gel (Purell) using a self-assessment questionnaire.
Interventions
- DRUG Silver Nanoparticle Gel
- DRUG alcohol-based hand gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659204
The ClinicalTrials.gov registry entry for NCT00659204 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madigan Army Medical Center, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Silver Nanoparticle Gel is the first listed.
NCT00659204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659204 about?
NCT00659204 is a clinical study titled "Efficacy of Silver Nanoparticle Gel Versus a Common Antibacterial Hand Gel". The purpose of this pilot study is to compare the antimicrobial efficacy of silver nanoparticle gel to a commercialized alcohol-based hand gel on bacterial counts isolated from the hands of 40 volunteers seeded with Serratia marcescens, a surrogate microbial marker. Specific aims of this study are: ...
What is the current status of trial NCT00659204?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2008-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00659204?
The interventions under investigation include: Silver Nanoparticle Gel (DRUG), alcohol-based hand gel (DRUG).
Who is sponsoring clinical trial NCT00659204?
This trial is sponsored by Madigan Army Medical Center, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.